BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Inaxaplin readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Inaxaplin\, from ClinicalTrials.gov estim
 ates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05312879-913@assetmemo.bio
DTSTAMP:20261121T005610Z
DTSTART;VALUE=DATE:20280602
DTEND;VALUE=DATE:20280603
SUMMARY:Inaxaplin: Phase 2/3 readout est. (NCT05312879)
DESCRIPTION:Inaxaplin\, phase 2/3\, Chronic Kidney Disease.\nStudy: Phase 2
 /3 Adaptive Study of VX-147 in Adult and Pediatric Participants With APOL1
 -Mediated Proteinuric Kidney Disease\nEstimated primary completion: 2 June
  2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/inaxaplin#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT05312879
URL:https://assetmemo.bio/drug/inaxaplin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
